Company Overview and News

6
8
All U.S. Homes Are Overvalued

2018-06-12 seekingalpha
My long-time pal Jesse Colombo, now at Real Investment Advice, recently linked on Twitter to a Zero Hedge article which quoted CoreLogic as saying more than half of American homes are overvalued. CoreLogic calls itself "a leading provider of consumer, financial and property data, analytics and services to business and government."
CLGX FNMA

43
Bay Area home prices hit another record high in April

2018-05-25 sfgate
Bay Area home prices set another record for the second straight month in April, as the median climbed to $850,000. That’s up 2.4 percent from March and 13.3 percent from April of last year, according to a CoreLogic report released Thursday.
FMCCO FMCCP FMCCM FMCCN FMCCI FMCCJ FMCCG FMCKO FMCKP FMCKM FMCKN FMCKK FMCKL FMCKI FMCKJ FMCC CLGX FMCCS FMCCT

6
CLGX / CoreLogic, Inc. POST-EFFECTIVE AMENDMENT

2018-05-10 sec.gov
Document As filed with the Securities and Exchange Commission on May 9, 2018
CLGX

6
CLGX / CoreLogic, Inc. POST-EFFECTIVE AMENDMENT

2018-05-10 sec.gov
Document As filed with the Securities and Exchange Commission on May 9, 2018
CLGX

6
CLGX / CoreLogic, Inc. REGISTRATION STATEMENT

2018-05-09 sec.gov
Document As filed with the Securities and Exchange Commission on May 9, 2018 Registration No. 333-__________
CLGX

6
6
Australia Home Prices Fall for Seventh Month, Led by Big Cities - Bloomberg

2018-05-01 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
CLGX

6
CLGX / CoreLogic, Inc. null

2018-04-28 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5A
CLGX

414
Oakmark Equity And Income Fund: Q1 2018

2018-04-23 seekingalpha
Includes detailed analysis of Oakmark Equity And Income Fund's positions in APC, CSL, CMCSA, LBRDA, LBRDK, CLGX, QRVO, REGN.
C.WSA CVS HCA GM.WS.A GM.WS.B GM.WS.C BKFS CMCSK BAC REGN BHGE ARNC BKI CGBBW MTW GM.WSB AEUA APC PM PFG CCV TEL CCZ FNF BAC C.WS.B CHTR CLGX FNFV C.WS.A C.PRP C.PRU GM C.PRS LBRDB QRVO C C.PRL C.PRJ CMCSA C.PRK CSL MA C.PRG LBRDK C.PRC BHI C.PRPCL CCV.CL JLL LBRDA UNH

58
6 Reasons Why FTI Consulting (FCN) is an Attractive Pick

2018-04-19 zacks
A prudent investment decision involves buying well-performing stocks at the right time while selling those that are at risk. A rise in share price and strong fundamentals signal a stock’s bullish run.
FCN ADPVV CLGX NVEE ADP WDC

74
Will Tax Cut Drive Omnicom (OMC) This Earnings Season?

2018-04-13 zacks
Omnicom Group Inc. (OMC - Free Report) is scheduled to report first-quarter 2018 results on Apr 17, before the opening bell.
WFC WFCNP RIGL WFC.WS GD SIG WFC.PRL MA WFC.PRJ SIG WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO CLGX WFC.PRN OMC WFC.PRY WFC.PRX WFC.PRW FLT WFC.PRV

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

20h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to CLGX / CoreLogic, Inc. on message board site Silicon Investor.

Core Logic
CUSIP: 21871D103